Page 1 of 5Free preview · 1–5

About this document

A five-page professional Q&A from Immunize.org about protecting healthcare personnel against hepatitis B. It covers vaccination eligibility, administration and schedules, post-vaccination anti-HBs testing, revaccination and vaccine nonresponse, chronic HBV infection, adult hepatitis B screening, and occupational post-exposure management. Includes a pre-exposure management algorithm and a post-exposure management table. Identified as Item #P2109, dated January 23, 2025.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

Experts from Immunize.org answer your questions about hepatitis B (HepB) vaccine. You’ll find additional Q&As about hepatitis B vaccine on the “Ask the Experts” section of immunize.org at www.immunize.org/askexperts/experts_ hepb.asp Hepatitis B Vaccination Which people who work in healthcare settings need hepatitis B vaccine? CDC recommends hepatitis B vaccination of everyone age 59 years and younger plus people 60 years and older who are at increased risk, including all healthcare personnel (HCP). In addition, the Occupational Safety and Health Administration (OSHA) requires that hepatitis B vaccine be offered to HCP who have a reasonable expectation of being exposed to blood or body fluids on the job. This requirement does not include personnel who would not be expected to have occupational risk (e.g., general office workers). At what anatomic site should hepatitis B vaccine be administered to adults? What needle size should be used? For adults, administer hepatitis B vaccine intramuscularly (IM) in the deltoid muscle. A 22- to 25-gauge, 1–1½ inch needle should be used. The gluteus muscle should not be used as a site for administering hepatitis B vaccine. For optimal protection, it is crucial that the vaccine be administered IM, not subcutaneously. How is Heplisav-B different from the 3-dose HepB vaccines? Heplisav-B (Dynavax) was approved by the Food and Drug Administration in November 2017 for persons 18 years of age and older. Heplisav-B contains a novel immunostimulatory adjuvant (CpG 1018) that binds to Toll-like receptor 9 to stimulate a directed immune response to HBsAg. It is provided in a single dose 0.5 mL vial and given as a 2-dose schedule. The doses should be separated by at least 4 weeks. Can you complete hepatitis B vaccination using different brands of HepB? A HepB vaccine series that was begun with one brand of hepatitis B vaccine may be completed with a different brand. When feasible, the same manufacturer’s vaccines should be used to complete the series. However, vaccination should not be deferred when the manufacturer of the previously administered vaccine is unknown or when the vaccine from the same manufacturer is unavailable. The 2-dose hepatitis B vaccine series only applies when both doses in the series consist of Heplisav-B. Series consisting of a combina- tion of 1 dose of Heplisav-B and a vaccine from a different manufacturer should consist of 3 total vaccine doses and should adhere to the 3-dose schedule minimum intervals of 4 weeks between dose 1 and 2, 8 weeks between dose 2 and 3, and 16 weeks between dose 1 and 3. Doses administered at less than the minimum interval should be repeated. However, a series containing 2 doses of Heplisav-B administered at least 4 weeks apart is valid, even if the patient received a single earlier dose from another manufacturer. If a person who works in a healthcare setting had one dose only of hepatitis B vaccine 5 years ago, should the series be restarted? No. The hepatitis B vaccine series should not be restarted when doses are delayed; rather, the series should be continued from where it stopped. Is it safe for HCP to be vaccinated during pregnancy? Yes. Engerix-B [GSK], Recombivax HB [Merck]), or Heplisav-B (Dynavax) may be administered during pregnancy. Current hepatitis B vaccines contain noninfectious hepatitis B surface antigen (HBsAg) and pose no risk to the fetus. HCP who breastfeed their babies can and should be vaccinated against hepatitis B if they haven’t been previously vaccinated. Receipt of the vaccine is not a reason to discontinue breast-feeding. Is there a recommendation for routine booster doses of hepatitis B vaccine? No. HCP who have documentation of receiving a complete series of hepatitis B vaccine and who subsequently tested positive for anti-HBs (defined as anti-HBs of ≥10 mIU/mL) are considered to be immune to hepatitis B. Immunocompetent people have long-term protection against HBV and do not need further testing or vaccine doses. Some immunodeficient persons, including those on hemodialysis, may need periodic booster doses of hepatitis B vaccine. We have a new employee with documentation of having received a series of hepatitis B vaccine as an adolescent. He now tests negative for hepatitis B surface antibody (anti-HBs). How should we manage him? ACIP recommends that HCP with written documentation of having received a properly spaced series of hepatitis B vaccine in the past (such as in infancy or adolescence) but who now test negative for anti-HBs should receive a single challenge dose of hepatitis B vaccine and be retested for anti-HBs 1–2 months later (see Figure 1). Those who test positive following the challenge dose are immune and require no further vaccination or testing. Those who test negative should complete a second series of hepatitis B vaccine on the usual schedule and be tested again 1–2 months after the last dose. Heplisav-B may be used to revaccinate new HCP (including the challenge dose) initially vaccinated with a vaccine from a different manufacturer in the past who have anti-HBs less than 10 mIU/mL upon hire or matriculation. For more information, see www.cdc.gov/ mmwr/volumes/67/rr/pdfs/rr6701-H.PDF, pages 21–22. Post-vaccination Anti-HBs Testing Which HCP need serologic testing after receiving a hepatitis B vaccine series? All HCP, including trainees, who have a high risk of occupational percutaneous or mucosal exposure to blood or body fluids (for example, HCP with direct patient contact, HCP at risk of needlestick or sharps injury, laboratory workers who draw, test or handle blood specimens) should have postvaccination testing for antibody to hepatitis B surface antigen (anti-HBs). Postvaccination testing Hepatitis B and Healthcare Personnel Immunize.org answers frequently asked questions about how to protect healthcare personnel FOR PROFESSIONALS www.immunize.org / FOR THE PUBLIC www.vaccineinformation.org www.immunize.org/catg.d/p2109.pdf Item #P2109 (1/23/2025) Scan for PDF continued on the next page

Page 2

anti-HBs ≥10 mlU/mL anti-HBs ≥10 mlU/mL should be done 1–2 months after the last dose of vaccine. Postvaccination testing for persons at low risk for mucosal or percutaneous exposure to blood or body fluids (for example, public safety workers and HCP without direct patient contact) likely is not cost-effective; however, those who do not undergo post- vaccination testing should be counseled to seek immediate testing if exposed. What should be done if a person’s post- vaccination anti-HBs test is negative (less than 10 mIU/mL) 1–2 months after the last dose of vaccine? Repeat a 2- or 3-dose HepB vaccine series (depending on vaccine brand) and test for anti-HBs 1–2 months after the final dose of the repeat series. Any HepB vaccine brand may be used for revaccination following an initial hepatitis B vaccine series from a different manufacturer. Any vaccine brand may be used to revaccinate new healthcare personnel (including the challenge dose) initially vaccinated with a vaccine from a different manufacturer in the distant past who have anti-HBs less than 10 mIU/mL upon hire or matriculation. If the test is still negative after a second vaccine series, the person should be tested for HBsAg and total anti-HBc to determine their HBV infection status. People who test negative for HBsAg and total anti-HBc should be considered vaccine non-responders and susceptible to HBV infection. They should be Hepatitis B and Healthcare Personnel (continued) page 2 of 5 Healthcare personnel (HCP) with documen- tation of a complete series of HepB vaccine but no documentation of anti-HBs ≥10 mIU/ mL who are at risk for occupational blood or body fluid exposure might undergo anti-HBs testing upon hire or matriculation. The algorithm at right will assist in the management of these people. It was adapted from CDC. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR 2018; 67(RR-1), available at www.cdc.gov/mmwr/volumes/67/rr/pdfs/ rr6701-H.pdf. note: Also available as stand-alone form at www.immunize.org/catg.d/p2108.pdf. Pre-exposure serologic testing may be recommended for all previously vaccinated HCP who were not tested 1 to 2 months after the third dose (such as people vaccinated as children or adolescents). Trainees, HCP in certain occupations, and HCP practicing in certain populations are at greater risk of exposure. Vaccinated HCP in these settings or occupations could benefit from pre-exposure serologic testing. Should be performed 1–2 months after the last dose of vaccine using a quantitative method that allows detection of the protective concentration of anti-HBs (≥10 mlU/mL) (e.g., enzyme-linked immunosorbent assay [ELISA]). A nonresponder is defined as a person with anti-HBs below 10 mIU/mL after 2 complete series of HepB vaccine. Persons who do not have a protective concentration of anti-HBs after revaccination should be tested for HBsAg. If positive, the person should receive appropriate management. See MMWR 2018;67(RR-1) at www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H. pdf for guidance on management of persons who do not respond to 2 complete series of HepB vaccine. ‡ * † Measure antibody to hepatitis B surface antigen (anti-HBs) if completed a primary series of HepB vaccines and no prior antibody test documenting anti-HBs ≥10 mlU/mL)* anti-HBs <10mlU/mL • Administer 1 dose of HepB vaccine. • Perform postvaccination serologic testing 1–2 months after vaccine dose.† FIGURE 1. Pre-exposure Management for Healthcare Personnel with a Documented Hepatitis B Vaccine Series Who Have Not Had Post- vaccination Serologic Testing anti-HBs <10 mlU/mL HCP need to receive hepatitis B evaluation for all exposures‡ • Complete a second series of HepB vaccine. • Perform postvaccination serologic testing 1–2 months after completion of series.† anti-HBs <10 mlU/mL No action needed for hepatitis B prophylaxis (regardless of the source of the patient’s hepatitis B surface antigen status) anti-HBs ≥10 mlU/mL continued on the next page www.immunize.org/catg.d/p2109.pdf / Item #P2109 (1/23/2025)

Page 3

counseled about precautions to prevent HBV infection and the need to obtain hepatitis B immune globulin (HBIG) prophylaxis for any known or likely exposure to HBsAg-positive blood. Those found to be HBsAg negative but total anti-HBc positive were infected in the past and require no vaccination or treatment. If the HBsAg and total anti-HBc tests are positive, the person should receive appropriate counseling for preventing transmission to others as well as referral for ongoing care to a specialist experienced in the medical management of chronic HBV infection. They should not be excluded from work. How often should I test HCP after they’ve received the hepatitis B vaccine series to make sure they’re protected? For immunocompetent HCP, periodic testing or periodic boosting is not needed. Post- vaccination testing (anti-HBs) should be done 1–2 months after the last dose of the hepatitis B vaccine series. If adequate anti-HBs (at least 10 mIU/mL) is present, no further antibody testing should be done, and no further HepB vaccine doses are recommended, even if sub- sequent antibody tests showed a titer of less than 10 mIU/mL. This information should be made available to the individual and recorded in his or her health record. If postvaccination testing is less than 10 mIU/mL, the vaccine series should be repeated and anti-HBs testing should be completed 1–2 months after the last dose of the second series. Does CDC now recommend routine pre- exposure anti-HBs testing for all HCP who were previously vaccinated but not tested? In general, no, but the type of testing (pre- exposure or post-exposure) depends on the healthcare worker’s profession and work setting. The risk for hepatitis B virus (HBV) infection for vaccinated HCPs can vary widely by setting and profession. The risk might be low enough in certain settings that assessment of hepatitis B surface antibody (anti-HBs) status and appropriate follow-up can be done at the time of exposure to potentially infectious blood or body fluids. This approach relies on HCP recognizing and reporting blood and body fluid exposures and might be applied on the basis of documented low risk, implementation, and cost considerations. Trainees, some occupations (such as those with frequent exposure to sharp instruments and blood), and HCP practicing in certain populations are at greater risk of exposure to blood or body fluid exposure from an HBsAg-positive patient. Vaccinated HCP in these settings/occupations would benefit from a pre-exposure approach. At our facility we do routine pre-employment anti-HBs testing regardless of whether the employee has documentation of a hepatitis B vaccination series and consider those with a positive antibody to be immune. Is this the recommended strategy? No. HCP with written documentation of receipt of a complete, properly spaced series of hepatitis B vaccine AND a positive anti-HBs can be considered immune to HBV and require no further testing or vaccination. Testing unvaccinated or incompletely vaccinated HCP (including those without written documentation of vaccination) is not necessary and is potentially misleading because anti-HBs of 10 mIU/mL or higher as a correlate of vaccine-induced protection has only been determined for persons who have completed a hepatitis B vaccination series. Persons who cannot provide written documentation of a complete hepatitis B vaccination series should complete the series, then be tested for anti-HBs 1 to 2 months after the final dose. Several physicians in our group have no documentation showing they received hepatitis B vaccine. They are relatively sure, however, that they received the doses many years ago. What do we do now? Because there is no documentation of vaccination, a vaccination series should be administered and postvaccination testing should be performed 1–2 months after the final dose of vaccine. There is no harm in receiving extra doses of vaccine. Postvaccination testing results should also be documented, including the date testing was performed. All healthcare settings should develop policies or guidelines to assure valid hepatitis B immunization. I’m a nurse who received a documented series of hepatitis B vaccine more than 10 years ago and had a positive follow-up titer (at least 10 mIU/mL). At present, my titer is negative (<10 mIU/ mL). What should I do now? Nothing. Data show that vaccine-induced anti-HBs levels might decline over time; however, immune memory (anamnestic anti-HBs response) remains intact following immunization. People with adequate anti-HBs concentrations that have declined to less than 10 mIU/mL are still protected against HBV infection. For HCP with normal immune status who have demonstrated adequate anti-HBs (≥10 mIU/mL) following full vaccination, booster doses of vaccine or periodic anti-HBs testing are not recommended. Non-responders or HCP with Chronic HBV Infection If an employee does not respond to hepatitis B vaccination (employee has had two full series of hepatitis B vaccine), does s/he need to be removed from activities that expose her/him to bloodborne pathogens? No. There are no regulations that require removal from job situations where exposure to bloodborne pathogens could occur; this is an individual policy decision within an organiza- tion. OSHA regulations require that employees, in jobs where there is a reasonable risk of exposure to blood, be offered hepatitis B vaccine. In addition, the regulation states that adequate personal protective equipment be provided and that standard precautions be followed. Check your state OSHA regulations regarding additional requirements. If there are no state OSHA regulations, federal OSHA regulations should be followed. Adequate documentation should be placed in the employee record regarding non-response to vaccination. HCP who do not respond after 2 complete series of vaccine should be tested for HBsAg and total anti-HBc to determine if they have chronic HBV infection. If the HBsAg and total anti-HBc tests are positive, HCP should receive appropriate counseling for preventing transmission to others as well as referral for ongoing care to a specialist experienced in the medical management of chronic HBV infection. People who are HBsAg-positive and who perform exposure-prone procedures should seek counsel from a review panel comprised of experts with a balanced perspective (e.g., infectious disease specialists and their personal physician[s]) regarding the procedures that they can perform safely. They should not be excluded from work. Nonresponders who test negative for HBsAg should be considered susceptible to HBV infection. They should be counseled about precautions to prevent HBV infection and the need to obtain HBIG prophylaxis for any known exposure to blood that is HBsAg-positive or if the HBsAg status of the source is unknown (see Table 1 below). Hepatitis B and Healthcare Personnel (continued) page 3 of 5 www.immunize.org/catg.d/p2109.pdf / Item #P2109 (1/23/2025) continued on the next page

Page 4

Can a person with chronic HBV infection work in a healthcare setting? Yes. HCP should not be discriminated against because of their hepatitis B status. All HCP should practice standard precautions, which are designed to prevent HBV transmission, both from patients to HCP and from HCP to patient. There is, however, one caveat concerning HBV-infected HCP. Those who have HBV levels 1000 IU/mL or 5000 genomic equivalents/mL or higher should not perform exposure-prone procedures (e.g., gynecologic, cardiothoracic surgery) unless they have sought counsel from an expert review panel and been advised under what circumstances, if any, they may continue to perform these procedures. For more information on this issue, see Updated CDC Recommendations for the Management of Hepatitis B Virus–Infected Health-Care Providers and Students, MMWR, 2012; 61(RR03):1-12. This document is avail- able at www.cdc.gov/mmwr/pdf/rr/rr6103.pdf. Hepatitis B Screening for All Adults Which HCP should be screened for hepatitis B infection and antibody? All adults 18 years and older, including HCP, are recommended to be screened once in a lifetime with the triple panel (HBsAg, anti-HBs, Hepatitis B and Healthcare Personnel (continued) page 4 of 5 Postvaccination serologic testing† No Yes Yes Yes No action needed No action needed Healthcare personnel status Documented responder§ after complete series Documented nonresponder¶ after 2 complete series Response unknown after complete series Unvaccinated/incompletely vaccinated or vaccine refusers Source patient (HBsAg) Positive/ unknown Negative Positive/ unknown Negative Any result Positive/ unknown Negative HBIG* HBIG x2 sepa- rated by 1 month HBIG x1 None HBIG x1 None Vaccination — Initiate revaccination Complete vaccination Complete vaccination No action needed Postexposure testing Postexposure prophylaxis Adapted from CDC. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR 2018; 67(RR-1), available at www.cdc.gov/ mmwr/volumes/67/rr/pdfs/rr6701-H.pdf. * HBIG should be administered intramuscularly as soon as possible after exposure when indicated. The effectiveness of HBIG when administered >7 days after percutaneous, mucosal, or nonintact skin exposures is unknown. HBIG dosage is 0.06 mL/kg. † Should be performed 1–2 months after the last dose of the HepB vaccine series (and 6 months after administration of HBIG to avoid detection of passively administered anti-HBs) using a quantitative method that allows detection of the protective concentration of anti-HBs (≥10 mIU/mL). § A responder is defined as a person with anti-HBs ≥10 mIU/mL after 1 or more complete series of HepB vaccine. ABBREVIATIONS HCP = healthcare personnel HBsAg = hepatitis B surface antigen anti-HBs = antibody to hepatitis B surface antigen HBIG = hepatitis B immune globulin ¶ A nonresponder is defined as a person with anti-HBs <10 mIU/mL after 2 complete series of HepB vaccine. ** HCP who have anti-HBs <10mIU/mL, or who are unvaccinated or incompletely vaccinated, and sustain an exposure to a source patient who is HBsAg-positive or has unknown HBsAg status, should undergo base- line testing for HBV infection as soon as possible after exposure, and follow-up testing approximately 6 months later. Initial baseline tests consist of total anti-HBc; testing at approximately 6 months consists of HBsAg and total anti-HBc. TABLE 1. Post-exposure management of healthcare personnel after occupational percutaneous and mucosal exposure to blood and body fluids, by healthcare personnel HepB vaccination and response status HCP testing (anti-HBs) Not indicated <10mIU/mL** <10mIU/mL ≥10mIU/mL —** — continued on the next page www.immunize.org/catg.d/p2109.pdf / Item #P2109 (1/23/2025)

Page 5

Hepatitis B and Healthcare Personnel (continued) page 5 of 5 and total anti-HBc) regardless of vaccination status. The purpose of this screening is to help identify persons who may not be aware that they are infected with hepatitis B and to help eliminate transmission of hepatitis B. HCP or others who are also recommended for hepatitis B vaccination should, ideally, be vaccinated at the same visit, after having blood drawn for screening. It is not necessary to delay vaccina- tion until screening results are available. If screening is not feasible before vaccination, vaccination should not be delayed. If screening is planned after vaccination, conduct screening at least one month (4 weeks) following the final dose of vaccine, since vaccination may result in transient false positive HBsAg test. Post-exposure Management How should a fully vaccinated employee with an unknown anti-HBs response be managed if they have a percutaneous or mucosal exposure to blood or body fluids from an HBsAg-positive or HBsAg-unknown source? Management of the exposed HCP depends on both the anti-HBs status of the HCP and the HBsAg status of the source patient. The HCP should be tested for anti-HBs and the source patient (if known) should be tested for HBsAg as soon as possible after the exposure. Testing the source patient and the HCP should occur simultaneously; testing the source patient should not be delayed while waiting for the HCP anti-HBs test results, and likewise, testing the HCP should not be delayed while waiting for the source patient’s HBsAg results. See Table 1 for management recommendations based on the results of testing. If an employee receives both HBIG and hepatitis B vaccine after a needlestick from a patient who is HBsAg positive, how long should one wait to check the employee’s response to the vaccine? Anti-HBs testing for HCP who receive both hepatitis B immune globulin (HBIG) and hepatitis B vaccine can be conducted as soon as 6 months after receipt of the HBIG. For more information on vaccination recommendations for healthcare personnel, see the following: 1 CDC. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, MMWR, 2013; 62(10):1–19, www.cdc.gov/mmwr/pdf/rr/ rr6210.pdf. 2 CDC. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR 2018; 67(RR-1), available at www.cdc.gov/ mmwr/volumes/67/rr/pdfs/rr6701-H.pdf. 3 CDC. Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022, MMWR 2022; 71(13), available at www.cdc.gov/mmwr/vol- umes/71/wr/pdfs/mm7113a1-H.pdf. 4 Immunize.org. “Healthcare Personnel Vaccination Recommendations,” www.immunize.org/catg.d/ p2017.pdf 5 Immunize.org. “Pre-exposure Management for Healthcare Personnel (HCP) with a Documented Hepatitis B Vaccine Series Who Have Not Had Post Vaccination Serologic Testing,” www.immunize.org/ catg.d/p2108.pdf 6 CDC Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023, MMWR 2023; 72(RR-1), available at www.cdc.gov/mmwr/volumes/72/rr/pdfs/ rr7201a1-H.pdf www.immunize.org/catg.d/p2109.pdf / Item #P2109 (1/23/2025)

Tags

Doxxly editorial guide

Hepatitis B and Healthcare Personnel: summary, contents and background

This guide helps you understand the scope of Hepatitis B and Healthcare Personnel before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

Hepatitis B and Healthcare Personnel is a 5-page documentcredited to Petra J. Grayling. A five-page professional Q&A from Immunize.org about protecting healthcare personnel against hepatitis B. It covers vaccination eligibility, administration and schedules, post-vaccination anti-HBs testing, revaccination and vaccine nonresponse, chronic HBV infection, adult hepatitis B screening, and occupational post-exposure management. Includes a pre-exposure management algorithm and a post-exposure management table. Identified as Item #P2109, dated January 23, 2025. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Hepatitis B, Healthcare personnel, Vaccination, Occupational health, Anti-HBs testing, Hepatitis B screening, Vaccine nonresponders, Post-exposure prophylaxis with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with Hepatitis B, Healthcare personnel, Vaccination, Occupational health, Anti-HBs testing, Hepatitis B screening, Vaccine nonresponders, Post-exposure prophylaxis. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 5 pages in the player.

  1. Part 1

    Hepatitis B

    Use this section of the reading guide to identify how Hepatitis B appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    Healthcare personnel

    Use this section of the reading guide to identify how Healthcare personnel appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    Vaccination

    Use this section of the reading guide to identify how Vaccination appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

  4. Part 4

    Occupational health

    Use this section of the reading guide to identify how Occupational health appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

  5. Part 5

    Anti-HBs testing

    Use this section of the reading guide to identify how Anti-HBs testing appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

  6. Part 6

    Hepatitis B screening

    Use this section of the reading guide to identify how Hepatitis B screening appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

  7. Part 7

    Vaccine nonresponders

    Use this section of the reading guide to identify how Vaccine nonresponders appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

  8. Part 8

    Post-exposure prophylaxis

    Use this section of the reading guide to identify how Post-exposure prophylaxis appears in Hepatitis B and Healthcare Personnel, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Petra J. Grayling

Doxxly credits Petra J. Grayling as the author or creator of Hepatitis B and Healthcare Personnel. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is immunize.org. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit immunize.org

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read Hepatitis B and Healthcare Personnel, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Explore more Medicine & Wellbeing resources

Frequently asked questions about Hepatitis B and Healthcare Personnel

Practical answers about reading, downloading and understanding this document on Doxxly.

More in Medicine & Wellbeing